Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Debt (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Total Debt for 10 consecutive years, with $755512.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Debt fell 10.09% year-over-year to $755512.0, compared with a TTM value of $755512.0 through Dec 2025, down 10.09%, and an annual FY2025 reading of $755512.0, down 10.09% over the prior year.
  • Total Debt was $755512.0 for Q4 2025 at Abvc Biopharma, down from $809103.0 in the prior quarter.
  • Across five years, Total Debt topped out at $1.9 million in Q4 2022 and bottomed at $402436.0 in Q3 2021.
  • Average Total Debt over 5 years is $868415.1, with a median of $843626.0 recorded in 2024.
  • Peak annual rise in Total Debt hit 152.74% in 2021, while the deepest fall reached 82.03% in 2021.
  • Year by year, Total Debt stood at $1.0 million in 2021, then soared by 81.49% to $1.9 million in 2022, then crashed by 52.51% to $899250.0 in 2023, then decreased by 6.56% to $840252.0 in 2024, then decreased by 10.09% to $755512.0 in 2025.
  • Business Quant data shows Total Debt for ABVC at $755512.0 in Q4 2025, $809103.0 in Q3 2025, and $871951.0 in Q2 2025.